Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Compound F can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.
Type:
Application
Filed:
May 4, 2021
Publication date:
June 15, 2023
Applicant:
AMGEN INC.
Inventors:
Austin G. SMITH, Michael T. CORBETT, Neil Fred LANGILLE, Kyle D. BAUCOM, Peter K. DORNAN, Gabrielle ST- PIERRE, Philipp C. ROOSEN, Sheng CUI, Roberto PROFETA
Abstract: Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed. The drug delivery device may include a housing, a container disposed in the housing and having an interior volume, a drug disposed in the interior volume, and a septum. The container may have an opening formed in an end surface and which communicates with the interior volume. The septum may include a proximal end inserted through the opening into the interior volume of the container. Additionally, the septum may include a distal end having a flange disposed outwardly of the proximal end and contacting the end surface of the container. At least an end portion of the flange may be made of a material that is permeable to a gaseous sterilizing agent.
Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
June 13, 2023
Assignee:
AMGEN INC.
Inventors:
Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
Abstract: An insertion mechanism for a drug pump includes an insertion mechanism housing; a sleeve; a rotational biasing member initially held in an energized state; a retraction biasing member and a hub connected to a proximal end of a needle, wherein the retraction biasing member is held initially in an energized state between the hub and the sleeve. The needle is inserted into a target tissue by the rotational biasing member and interaction between the hub and housing. Retraction of the needle is caused by decompressing or de-energizing of the retraction biasing member. A drug delivery pump includes an activation mechanism, a drive mechanism, a sterile access connection, and the insertion mechanism. Assembly and operation methods are provided.
Type:
Grant
Filed:
November 18, 2020
Date of Patent:
June 13, 2023
Assignee:
AMGEN INC.
Inventors:
Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV
Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
Type:
Application
Filed:
October 14, 2022
Publication date:
June 8, 2023
Applicants:
CytomX Therapeutics, Inc., Amgen, Inc.
Inventors:
Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound D, wherein OPG and R1 are described herein. Compound D can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.
Abstract: Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.
Type:
Application
Filed:
May 5, 2021
Publication date:
June 1, 2023
Applicant:
AMGEN INC.
Inventors:
Austin G. SMITH, Jason S. TEDROW, Gabrielle ST-PIERRE, Oliver Ralf THIEL, Liang HUANG, Philipp C. ROOSEN, John T. COLYER, Kyle D. BAUCOM, Ari ERICSON, Matthew G. BEAVER, Rahul P. SANGODKAR, Michael A. LOVETTE, Robert Ronald MILBURN, Alan H. CHERNEY, Sheng CUI
Abstract: Described herein are stable high concentration bispecific antibody construct formulations, wherein the formulations have less than 2% high molecular weight species of the bispecific antibody construct in the formulation under storage conditions at various time points.
Type:
Application
Filed:
April 28, 2021
Publication date:
June 1, 2023
Applicant:
AMGEN INC.
Inventors:
Twinkle R. Christian, Bharadwaj Jagannathan
Abstract: Systems and methods for injecting a drug and detecting tissue induced back pressure are disclosed. A drug delivery system may include a reservoir filled or fillable with a drug, an administration member connected or connectable in fluid communication with the reservoir, a drive assembly, and a pressure sensor. The administration member may be configured for insertion into and subsequently retraction from a patient. The drive assembly may be configured to urge the drug from the reservoir to deliver a dose of the drug to the patient via the administration member. The pressure sensor may be configured to detect tissue back pressure during use of the drug delivery system, including after dose completion and prior to retraction of the administration member. The drug delivery system may be controlled in a manner that accounts for the tissue back pressure measurement.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
May 30, 2023
Assignee:
AMGEN INC.
Inventors:
Daniel Eduardo Groszmann, Scott Robert Gibson
Abstract: The devices, assemblies, and methods described herein utilize photoacoustic principals to create a jet of fluid using a ultrasonic resonance member and a pulsed laser light beam. The ultrasonic resonance member is a treated substrate having an liquid interface surface in contact with a fluid. When a pulsed laser light beam is applied to the treated substrate, pressure is generated via induced ultrasonic waves to urge the fluid into a jet stream.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
May 30, 2023
Assignee:
AMGEN INC.
Inventors:
Mehran Mojarrad, Scott R. Gibson, Heejin Lee
Abstract: The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein serum albumin is fused to the C-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
May 30, 2023
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Benno Rattel, Matthias Friedrich, Peter Kufer, Patrick Hoffmann, Tobias Raum, Markus Münz, Ines Herrmann, Ralf Lutterbüse, Elisabeth Nahrwold
Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
Type:
Application
Filed:
February 11, 2021
Publication date:
May 25, 2023
Applicant:
AMGEN INC.
Inventors:
Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
Abstract: Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
Abstract: Provided herein are methods of treating a subject having a neoplastic disease, comprising administering to the subject a KIF18A inhibitor in an amount effective to treat the neoplastic disease a neoplastic disease in a subject. Also provided are methods of inducing or increasing tumor regression in a subject with a tumor and methods of reducing tumor or cancer growth in a subject. In exemplary aspects, the method comprises administering to the subject a KIF18A inhibitor. Methods of inducing or increasing death of tumor or cancer cells in a subject comprising administering to the subject a KIF18A inhibitor are also provided herein. Advantageously, the KIF18A inhibitors selectively treat the neoplastic disease, induce or increase tumor regression, and/or induce or increase death of tumor or cancer cells without overt toxicity to normal somatic cells.
Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.
Type:
Application
Filed:
April 8, 2019
Publication date:
May 11, 2023
Applicant:
AMGEN INC.
Inventors:
YuMei XIONG, Kenneth William WALKER, Murielle Marie VENIANT ELLISON
Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
May 9, 2023
Assignee:
AMGEN INC.
Inventors:
Irwin Chen, Su Chong, Essa Hu Harrington, Fang-Tsao Hong, Jason C. Long, Leslie P. Miranda
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.